CLINICAL UTILITY OF CAVeA2T2 SCORE FOR ASSESSING THE SURVIVAL OF BRACHIOCEPHALIC ARTERIOVENOUS FISTULA

Authors

  • Rashid Usman CMH Lahore Medical College and CMH Hospital Lahore
  • Hammad Malik CMH Lahore Medical College
  • Mudassar Mehmood CMH Lahore Medical College
  • Muhammad Waseem Anwar CMH Lahore Medical College
  • Amna Shahab CMH Lahore Medical College

Abstract

Background: There are not many error proof clinical scores to assess the native dialysis access. CAVeA2T2 score is a recent tool in use. Objective of the study is to assess the clinical utility of CAVeA2T2 scoring system in predicting the survival rate of brachiocephalic arteriovenous fistula (BC-AVF). Methods: All consecutive patients fulfilling the inclusion criteria for BC-AVF from January 2016 to January 2018 were included. According to their CAVeA2T2 score they were divided into two groups (Group A: < 2 and Group B: ≥2). Cumulative primary and secondary patency survival of BC-AVF for both groups were measured. Results: A total of 112 BC-AVFs were analysed. Mean age was 42±SD 14 years (M: F =5:1). Mean CAVeA2T2 score was 1.45±1.8. In terms of primary patency, there was no statistically significant difference between two groups (p=0.074, p = 0.229 and p=0.357 at 6 weeks, 6 months and 12 months respectively). However, the difference was significant in terms of secondary patency (p=0.002, p=0.036 and p=0.032 at 6 weeks, 6 months and 12 months respectively). On comparing the cumulative survival between two groups; a significantly low primary patency rate survival (Log Rank x2 = 12.9, p-value = 0.001) and secondary patency rate survival (Log Rank x2 = 7.6, p-value = 0.001) of BC-AVF was found in Group B. Conclusion: We found CAVeA2T2 score an easily applicable and useful tool to assess the patency and survival of BC-AVF. Patients have a poor patency and significantly low survival rate when their CAVeA2T2 score was ≥2.Keywords: Fistula survival; Patency rate; Score; Arteriovenous fistula

Author Biographies

Rashid Usman, CMH Lahore Medical College and CMH Hospital Lahore

Assistant Professor of SurgeryDepartment of SurgeryCMH Lahore Medical College

Hammad Malik, CMH Lahore Medical College

Department of Surgery

Mudassar Mehmood, CMH Lahore Medical College

Assistant Professor of SurgeryDepartment of SurgeryCMH Lahore Medical College

Muhammad Waseem Anwar, CMH Lahore Medical College

Assistant Professor of SurgeryDepartment of SurgeryCMH Lahore Medical College

Amna Shahab, CMH Lahore Medical College

Associate Professor of SurgeryDepartment of SurgeryCMH Lahore Medical College

References

Woo K, Ulloa J, Allon M, Carsten CG, Chemla ES, Henry ML, et al. Establishing patient-specific criteria for selecting the optimal upper extremity vascular access procedure. J Vasc Surg 2017;65(4):1089–103.

Masengu A, Maxwell AP, Hanko JB. Investigating clinical predictors of arteriovenous fistula functional patency in a European cohort. Clin Kidney J 2016;9(1):142–7.

Lee HS, Song YR, Kim JK, Joo N, Kim C, Kim HJ, et al. Outcomes of vascular access in hemodialysis patients: Analysis based on the Korean National Health Insurance Database from 2008 to 2016. Kidney Res Clin Pract 2019;38(3):391–8.

Rayner HC, Pisoni RL, Gillespie BW, Gillespie BW, Goodkin DA, Akiba T, et al. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2003;63(1):323–30.

Copeland TP, Hye RJ, Lawrence PF, Woo K. Association of Race and Ethnicity with Vascular Access Type Selection and Outcomes. Ann Vasc Surg 2020;62:142–7.

Al-Balas A, Lee T, Young CJ, Allon M. Choice of a second vascular access in hemodialysis patients whose initial arteriovenous fistula failed to mature. J Vasc Surg 2018;68(6):1858–64.

Monroy-Cuadros M, Yilmaz S, Salazar-Banuelos A, Doig C. Risk factors associated with patency loss of hemodialysis vascular access within 6 months. Clin J Am Soc Nephrol 2010;5(10):1787–92.

Huang YT, Chang YM, Chen IL, Yang CL, Leu SC, Su HL, et al. Heart rate variability during hemodialysis is an indicator for long-term vascular access survival in uremic patients. PLoS One 2017;12(3):e0172212.

Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006;48(Suppl 1):S176–247.

Martinez LI, Esteve V, Yeste M, Artigas V, Llogostera S. Clinical Utility of a New Predicting Score for Radiocephalic Arteriovenous Fistula Survival. Ann Vasc Surg 2017;41:56–61.

Smith GE, Gohil R, Chetter IC. Factors affecting the patency of arteriovenous fistulas for dialysis access. J Vasc Surg 2012;55(3):849–55.

Ma L, Zhao S. Risk factors for mortality in patients undergoing hemodialysis: A systematic review and meta-analysis. Int J Cardiol 2017;238:151–8.

Lee KG, Chong TT, Goh N, Achudan S, Tan YL, Tan RY, et al. Outcomes of arteriovenous fistula creation, effect of preoperative vein mapping and predictors of fistula success in incident haemodialysis patients: A single-centre experience. Nephrology (Carlton) 2017;22(5):382–7.

Hossain S, Sharma A, Dubois L, DeRose G, Duncan A, Power AH. Preoperative point-of-care ultrasound and its impact on arteriovenous fistula maturation outcomes. J Vasc Surg 2018;68(4):1157–65.

Jamil M, Usman R. Predictive parameters for successful functional maturation of native arteriovenous fistula. J Ayub Med Coll Abbottabad 2015;27(4):821–4.

Lok CE, Allon M, Moist L, Oliver MJ, Shah H, Zimmerman D. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol 2006;17(11):3204–12.

Vernaglione L, Mele G, Cristofano C, Distratis C, Perrone F, Frascina M, et al. Comorbid conditions and gender impact the primary survival of distal radiocephalic arteriovenous fistula inpatients on long-term hemodialysis. J Nephrol 2005;18(3):276–81.

Bosanquet DC, Rubasingham J, Imam M, Woolgar JD, Davies CG. Predicting outcomes in native AV forearm radio-cephalic fistulae; the CAVeA2T2 scoring system. J Vasc Access 2015;16(1):19–25.

Downloads

Published

2020-06-28

Most read articles by the same author(s)